Clinical trials: SARS-CoV 2
Covid19, Coronavirus
QuadraMune(TM) for Prevention of COVID-19
QuadraMune(TM) is a nutritional supplement which has previously been demonstrated to possess antiinflammatory and immune modulatory activity based on in vitro and pilot in vivo studies.
- Conditions
- Covid19, Coronavirus, SARS-CoV 2
- Trial name
- NCT04421391
- Testing
- QuadraMune(TM)
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Therapeutic Solutions International
COVID, SARS-CoV 2
Seroepidemiological Study of SARS-CoV-2 (COVID-19) Infection in Population Subgroups in the State of São Paulo
Seroepidemiological Study of SARS-CoV-2 Infection in Population Subgroups in the State of São Paulo
- Trial name
- NCT04408014
- Testing
- Serological test, Nasopharyngeal Swab, Oropharyngeal Swab
- Where
- Brazil
- Volunteers
- 18,901 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Coronavirus Infection, SARS-CoV 2
Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19
This is a phase I/IIa trial to evaluate the safety, tolerability and immunological profile of INO-4800 administered by intradermal (ID) injection followed by electroporation (EP) using the CELLECTRA® 2000 device in healthy adults…
- Trial name
- NCT04447781
- Testing
- INO-4800, CELLECTRA® 2000, Saline-sodium citrate (SSC) buffer
- Where
- 2 sites in South Korea
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
COVID-19, SARS CoV 2 Virus
Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine
The primary objective of this effort will be to optimize and operationalize innovative passive surveillance systems and in parallel, the effort will identify, evaluate, and transition groundbreaking new technologies in…
- Conditions
- COVID-19, SARS CoV 2 Virus, COVID-19 Pneumonia, COVID-19 Respiratory Infection
- Trial name
- COVID-19 (NCT06402318)
- Testing
- A&M Breathalyzer PROTECT Kiosk
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- The Geneva Foundation
SARS CoV 2 Infection, SARS-CoV-2 Acute Respiratory Disease
Efficacy and Safety of Nasal Spray Solution Containing Human IgG1 Anti-COVID-19 Antibody Cocktail
Hypromellose-based nasal spray solution containing human IgG1 anti-SARS-CoV-2 antibody cocktail is a medical device innovated to provide the dual-action physical barrier on nasal mucosa that aids the natural defence in which the…
- Trial name
- NCT05358873
- Testing
- Human IgG1 anti-SARS-CoV-2 antibody cocktail
- Where
- Thailand
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Chulalongkorn University
Covid19, SARS-CoV Infection
A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults
This is a Phase 2, randomized, placebo-controlled, and observer-blind study in healthy adults. The study will evaluate the safety, tolerability, and immunogenicity of the SARS-CoV-2 RNA vaccine candidate against COVID-19: As 2…
- Conditions
- Covid19, SARS-CoV Infection, Corona Virus Infection
- Trial name
- NCT04668339
- Testing
- ARCT-021 single dose priming, ARCT-021 two lower dose priming, ARCT-021 two higher dose priming
- Where
- 15 sites in United States, Singapore
- Volunteers
- 581 people, healthy volunteers welcome
- Sponsor
- Arcturus Therapeutics, Inc.
Apnea, Obstructive Sleep, SARS CoV 2 Infection
Impact of Sleep Disorders on Innate Immunity in COVID-19 Patients
Sleep is an important modulator of the immune response, whereby sleep disturbances (ie, poor sleep quality, insufficient sleep and/or primary sleep disorder, obstructive sleep apnea (OSA)) contribute to inflammatory disease risk…
- Trial name
- NCT06341374
- Testing
- Influvac Tetra
- Where
- Spain
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Parc Taulí Hospital Universitari
COVID-19, Vaccine-Preventable Diseases
The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection
The purpose of this research study is to find out how well two different 2023-2024 updated COVID-19 vaccines protect people from COVID-19 (the disease caused by the SARS-CoV-2 virus), and to determine if getting a 2023-2024…
- Conditions
- COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection, Upper Respiratory Tract Infection
- Trial name
- BEEHIVE (NCT06065176)
- Testing
- Novavax COVID-19 vaccine (2023-2024 formula XBB containing), Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing)
- Where
- United States
- Volunteers
- 1,188 people, healthy volunteers welcome
- Sponsor
- Sarang K. Yoon, DO, MOH
COVID-19, SARS-CoV 2
Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection
This is a prospective, double-blind, randomized, placebo-controlled study in two distinct cohorts to evaluate the efficacy and safety of hydroxychloroquine in the prevention of COVID-19 infection.
- Trial name
- NCT04372017
- Testing
- Hydroxychloroquine, Vitamin D
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Sanford Health
COVID-19 Disease
ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects
An open label phase 2 trial to evaluate safety, tolerability and immunogenicity of the ABNCoV2 vaccine after intramuscular (IM) application.
- Trial name
- NCT05077267
- Testing
- ABNCoV2 100ug, ABNCoV2 50ug
- Where
- 2 sites in Germany
- Volunteers
- 197 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
SARS CoV 2 Infection, COVID-19 Breakthrough
SARS-CoV-2 Specific Antibody Responses and Impact for COVID-19 Disease in Ethiopia
In this study we aim to characterize SARS CoV-2 strain specific immune response (SARS-CoV-2 Spike IgG) in health care workers and general populations at the Jimma Medical Center and the St.
- Conditions
- SARS CoV 2 Infection, COVID-19 Breakthrough, COVID-19 Recurrent
- Trial name
- CoVICIS (NCT06435403)
- Where
- 2 sites in Ethiopia
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Michael Hoelscher
SARS-CoV 2, COVID
Precision Immunology to Determine the Immune Response in Patients With COVID-19
To better understand the immune response to SARS-CoV-2 infection, we devised a precision immunology approach to systematically study the immune function of different patient cohorts
- Trial name
- NCT04360733
- Testing
- Blood draw
- Where
- Germany
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Bonn
SARS-CoV 2
SARS-CoV2 (COVID-19) Diagnosis in Human Saliva by MALDI-TOF MS Profiling
Since March 2020, SARS-CoV2 virus (nCoV19; COVID-19) is considered pandemic. Its high rate of spread and infection in the human population and the lack of effective and validated treatment have led the authorities of several…
- Trial name
- CoviDiagMS (NCT04460638)
- Testing
- Saliva collection, Clinical assessment
- Where
- France
- Volunteers
- 779 people, healthy volunteers welcome
- Sponsor
- Direction Centrale du Service de Santé des Armées
Infections, Respiratory, Virus Diseases
A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults
Originally, the study was planned to include two parts, i.e., Part A and Part B, however Part B was cancelled due to changes in the overall clinical development plan.
- Conditions
- Infections, Respiratory, Virus Diseases, Infection Viral, Vaccine Adverse Reaction
- Trial name
- NCT04380701
- Testing
- BNT162a1, BNT162b1, BNT162b2
- Where
- 5 sites in Germany
- Volunteers
- 512 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
SARS-CoV 2, Infection
GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19)
This clinical trial will evaluate the safety, tolerability and effectiveness of topical GLS-1200 nasal spray to reduce the incidence of confirmed, symptomatic SARS-CoV-2 infection.
- Trial name
- NCT04408183
- Testing
- GLS-1200
- Where
- 3 sites in United States
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- GeneOne Life Science, Inc.
SARS-CoV Infection, Covid19
Use of Hypochlorous Acid as Prophylaxis in Health Personnel at High Risk of Infection by SARS-CoV 2 (COVID19)
The pandemic caused by SARS-CoV-2 is a global emergency present in 6 continents including 66 countries, incurring a shortage of effective and safe therapeutic alternatives that can contribute to reducing the risk of…
- Conditions
- SARS-CoV Infection, Covid19, Infection Viral
- Trial name
- NCT04684550
- Testing
- Stabilized hypochlorous acid
- Volunteers
- healthy volunteers welcome
- Sponsor
- Hospital Universitario San Ignacio
SARS-CoV 2
Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years.
The study will be a randomized, partially-blinded, prime-boost, staggered dose-escalation Phase 1 study intended to assess the safety, tolerability, and immunogenicity of the Coronavirus-Like Particle COVID-19 Vaccine at three…
- Trial name
- NCT04450004
- Testing
- Intramuscular Vaccine
- Where
- 2 sites in Canada
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Medicago
COVID-19, SARS-CoV 2
Network-Targeted Strategies for Efficient Community SARS-CoV-2 (COVID-19) Sampling
The primary objective is to use "network targeted sampling design" to detect active and/or undiagnosed cases of COVID-19 in the community and determine the spread or distribution of 1) active infection, and 2) past exposure.
- Trial name
- Snowball (NCT04437706)
- Where
- United States
- Volunteers
- 602 people, healthy volunteers welcome
- Sponsor
- Duke University
COVID-19, Vaccine Reaction
Evaluation of the Immunogenicity and Safety of Ad26.COV2.S's COVID-19 Vaccine
Phase II, non-randomized, open-label, comparative, national, multicenter trial in Mali, aimed to assess the humoral vaccine immune response induced by Ad26.COV2.S vaccine in 200 adults one month after receiving the complete…
- Conditions
- COVID-19, Vaccine Reaction, SARS CoV 2 Infection, Vaccine Adverse Reaction
- Trial name
- CoviComMali (NCT05409261)
- Testing
- Ad26.COV2.S
- Where
- Mali
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
COVID-19 Pandemic, Immunogenicity
Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults
Under protocol versions 1.01-1.06: The five recently emerged SARS-CoV2 variants that were designated as VOCs are the Alpha variant, Beta variant, Gamma variant, Delta variant and the Omicron variant.
- Conditions
- COVID-19 Pandemic, Immunogenicity, SARS CoV 2 Infection, COVID-19
- Trial name
- SH-MO-214 (NCT05383560)
- Testing
- mRNA-1273.214 Vaccine, MRNA-1273 Vaccine, MRNA-1273.222 Vaccine
- Where
- Israel
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Sheba Medical Center